Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

1.98
+0.05002.59%
Post-market: 1.96-0.0200-1.01%19:55 EDT
Volume:2.03M
Turnover:3.97M
Market Cap:74.10M
PE:-1.35
High:2.00
Open:1.96
Low:1.92
Close:1.93
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:0.78
T/O Rate:11.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.65
PE(LYR):-1.48

Loading ...

Tenax Therapeutics Q2 Net Income USD -17.803 Million

Reuters
·
Jul 31

Tenax Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Jul 31

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Jul 31

Tenax Therapeutics Q2 Operating Expenses USD 18.784 Million

THOMSON REUTERS
·
Jul 31

Tenax Therapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $35

THOMSON REUTERS
·
Jul 28

Tenax Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Jul 28

Tenax Therapeutics initiated with a Buy at Canaccord

TIPRANKS
·
Jul 28

Canaccord Genuity Initiates Tenax Therapeutics at Buy With $35 Price Target

MT Newswires Live
·
Jul 28

Tenax Therapeutics Initiated at Outperform by Evercore ISI Group

Dow Jones
·
Jul 22

Tenax Therapeutics (TENX) Gets a Buy from LifeSci Capital

TIPRANKS
·
Jul 11

Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)

TIPRANKS
·
Jul 10

LifeSci Capital Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

TIPRANKS
·
Jul 06

Tenax Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 03

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June

MT Newswires Live
·
Jul 02

Tenax Therapeutics is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 02

Tenax Therapeutics highlights key Phase 3 LEVEL trial

TIPRANKS
·
Jul 02

Tenax Therapeutics Flags Announcement on LEVEL Trial Data Presentation at ESC Congress 2026

Reuters
·
Jul 02

Tenax Therapeutics Announces Late-breaking Presentation of Level Clinical Trial Data at Esc Congress 2026

THOMSON REUTERS
·
Jul 02

Tenax Therapeutics: Extends US Regulatory Approval Deadline to December 31, 2035 Via Sixth Amendment to Orion License - SEC Filing

THOMSON REUTERS
·
Jul 01